Back HIV/AIDS

HIV / AIDS

AIDS 2016: Young Women Treated Very Early Stay HIV Negative and Preserve Immune Function

A group of youngSouth African women who were diagnosed during very HIV early infection and immediately given antiretroviral therapy (ART) preserved their CD4 cell counts and the function of cells that HIV normally disrupts, according to a study presented at the 2016 Towards an HIV Cure Symposium, which preceded the 21st International AIDS Conference this week in Durban, South Africa. The majority of them never seroconverted, staying HIV-negative despite having evidence of low levels of HIV infection in their cells.

alt

AIDS 2016: PrEP Use Exceeds 79,000 in U.S., But Some Groups Lagging Behind

More than 79,000 people in the U.S. have started Truvada for pre-exposure prophylaxis (PrEP) over the past 4 years, according to the latest results from a survey of retail pharmacies by Gilead Sciences, presented today at the 21st International AIDS Conference (AIDS 2016) in Durban. Yet while large gains in PrEP use have been seen among men in cities with large gay communities, some groups are not benefitting as much as they could.

alt

AIDS 2016: Gains in Curbing HIV Could Be Lost Without Continued Commitment

Participants at the 21st International AIDS Conference (AIDS 2016), taking place this week in Durban, South Africa, reviewed the remarkable gains that have been made in access to HIV treatment and new prevention tools since the conference was last held here 16 years ago. But researchers, activists, and government leaders agreed that this progress could be reversed if stakeholders do not commit to increased funding and respect for the human rights of key populations at risk.

alt

AIDS 2016: Researchers Now Focusing on Best Ways to Get PrEP to People Who Need It

Speaking to a pre-conference meeting on HIV pre-exposure prophylaxis (PrEP) ahead of the 21st International AIDS Conference (AIDS 2016), International AIDS Society president Chris Beyrer reminded delegates that when the International AIDS Conference was last held in Durban in the year 2000, the event was notable for drawing attention to the enormous gap in access to HIV treatment between rich and poorer countries. That conference began the treatment access era. "Now is really the time to start the PrEP access era," Beyrer said.

alt

AIDS 2016: International AIDS Conference Starts Next Week in Durban

The 21st International AIDS Conference (AIDS 2016) opens next Monday, July 18, in Durban, South Africa, 16 years after the groundbreaking conference in the same city that put the spotlight on global access to new life-saving treatment for people living with HIV and AIDS. This year's theme -- Access, Equity, Rights Now -- recognizes the barriers that still need to be overcometo achieve universal access. HIVandHepatitis.comand collaborator Aidsmap.comwill provide on-site coverage starting on July 17. Follow @HIVandHepatitison Twitter and visit our AIDS 2016 conference page (coming soon) or Facebook pagefor the latest news.

alt

AIDS 2016: Progress Towards 90-90-90 Targets is Promising, But Funding Is the Critical Step

The United Nations 90-90-90 targets for HIV testing, treatment, and viral suppression are achievable by 2020 in many high-burden countries, but donor retreat is now the biggest threat to widespread success, delegates agreed at the UN 90-90-90 Target Workshop ahead of the 21st International AIDS Conference (AIDS 2016) in Durban.

alt

ASM Microbe 2016: Switching from Tenofovir DF to TAF Improves Bone and Kidney Safety

People with HIV who switched from the older tenofovir disoproxil fumarate (TDF) formulation to tenofovir alafenamide (TAF) were more likely to maintain viral load suppression and showed improvements in bone density and kidney function biomarkers, according studies presented at the 2016 ASM Microbe conference last month in Boston.

alt